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Abstract
Background: Methenamine is a worldwide antibacterial agent for urinary system
infections in human and animals. The effect of methenamine consumption during early
phase of pregnancy is not fully clarified in previous studies. Vascular development is
the essential part of the early embryonic growth.
Objective: In this study, we used chicken chorioallantoic membrane to evaluate the
effects of methenamine administration on angiogenesis process as a model.
Materials and Methods: In this experimental study, 20 Ross 308 eggs (mean weight
55 ± 4) were incubated. The eggs were divided into two equal groups (n = 10/each).
In the first group, methenamine (150 mg/kg egg weight) was injected on the shell
membrane, and in the second group (control group) phosphate-buffered salineas
injected. Methenamine was inoculated at 96 and 120 hrafter incubation; 24 hrafter the
last inoculation, the eggs were removed and the egg’s shell was incised. Then, the
development of vascular network and vascular endothelial growth factor Aexpression
was evaluated.
Results: Angiogenesis was significantly decreased after methenamine treatment.
The indexes such as areas containing vessels, the vessels’ length, the percentage
of angiogenesis developing areas, and vascular complexity in the treatment group
receiving methenamine were significantly reduced compared to the control group.
Vascular endothelial growth factor Aexpression was suppressed in the methenamine
treated group.
Conclusion: According to the achieved results, it was defined that methenamine could
have an inhibitory effect on the growth and development procedures of extraembryonic
vasculature.
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1. Introduction
Methenamineis aheterocyclic organic
compound with the formula (CH2)6N4 that
has been widely used as a safe and relatively
effective antibacterial for urinary tract infections.
Methenamine, in acid pH of urine, releases
ammonia and formic acid, and the formic acid is
bactericidal (1). In case of chronic urinary infection,
methenamine is a good choice for decreasing
bacterial growth (lowering urine bacterial count)
or for prophylaxis (keeping urine sterile after
it has been cleared from bacterial infection by
antibiotics) (2). Considerations that encourage
the methenamineadministration include: i) its
antibacterial effect in vitro, ii) the lack of effect
on gut flora, iii) the apparent absence of bacterial
resistance to low formaldehyde concentrations,
iv) its relatively cheapness, and v) its reported low
toxicity (3).
Production and proliferation of blood vessels
are procedures necessary for the normal growth
and development of tissue (4). After puberty,
angiogenesis does not occur physiologically,
except in the reproductive system of female,
and in the placenta during pregnancy. The
expansion of vascular networks during pregnancy
or normal and pathological angiogenesis is
related to the growth factors and interactions
between cellular and extracellular matrix (5).
During embryogenesis, development of blood
vessels is done by two procedures including
vasculogenesis and angiogenesis (6). Growth
factors’ roles in both procedures are well-clarified.
Among these growth factors, the most two
important factors are vascular endothelial growth
factor (VEGF) and basic fibroblast growth factor
(bFGF) that promote both embryonic vascular
network initial development and new blood
vessels formation during reproductive cycle
of female, development, and wound healing
(7). During pregnancy, vascularization of the
human embryo takes place in the early stages,
approximately the second week post conception
and is appeared first in the extraembryonic areas
(8). Vascularization of the chorionic villi is a
cornerstone for embryonic development and that
normal chorionic villous vascularization is essential
for the undisturbed development of pregnancy
(9).
Hydropic degeneration, fibrosis and lower level
of vascular density have been detected in the
cases of intrauterine embryonic death (10). Other
illnesses and syndromes such as pre-eclampsia,
intrauterine growth restriction, gestational diabetes
and maternal diabetes mellitus, which disrupt the
process of angiogenesis, can also damage the
developing fetus (11). In the case of thalidomide
toxicity, it has been reported that all congenital
defects could be due to antiangiogenic action
of thalidomide during embryogenesis (12).
Therefore, any drug that has an effect on the
angiogenesis process will most likely affect the
development of the fetus during pregnancy.
There are a few studies on methenamine toxicity
during pregnancy in literature. In the FDA grade
of drug consumption during pregnancy, the
grade of methenamine is C, which means that
there is no standard trial to prove the safety of
methenamine during pregnancy (13). The chick
embryo chorioallantoic membrane (CAM) is an
extraembryonic membrane that is commonly used
in vivo to study angiogenic or antiangiogenic
substances (14).
To the best of our knowledge, there is no
investigation on angiogenic/antiangiogenic
properties of methenamine. In this study, we tried
to study the angiogenic/antiangiogenic properties
of methamine in order to get informed about its
possible side effects during pregnancy. We also
identified the possible interaction of methenamine
with VEGF-A protein by computer-aided simulation.
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2. Materials and Methods
This section explained in terms of A) effect
of methenamine extract on the early embryonic
angiogenesis, B) effect of methenamine extract on
the expression of VEGF-A, and C) assessment of
methenaminebinding to VEGF-Awith the help of a
computer program.
2.1. Effect of methenamine on early
embryonic angiogenesis
Angiogenesis in the early embryonic phase and
the effect of methenamine on this process was
evaluated by the evaluation of vascularization on
the chick’s extraembryonic membrane (EEM). The
procedure is explained as follows.
2.1.1. Eggs
Fertile chicken eggs (Ross 308) with the average
egg-weight of 52.5 ± 0.6 gr were obtained from
the Mahan Breeder Company, Kerman, Iran. In
this farm, the condition to rear breeder birds was
standard.
2.1.2. Embryo treatment and image
acquisition
The eggs were kept in vertical position in
an electrical incubator (Belderchin Damavand Co.
PLC-DQSH, Tehran, Iran) at a temperature of 37.5°C
and relative humidity of 60%. During all procedure,
70% ethanol solution was used for the disinfection
of equipment that were in contact with the eggs.
On the fourth day (or: on day 4) of incubation,
an orifice with diameter of approximately 2 mm
in the eggshell at the site of the air space was
made. An injection of 50 μl of either methenamine
(150 mg/kg) or sterile phosphate-buffered saline as
placebo was done in the created site on eggshell
as a single drop on the inner shell membrane. The
inner shell membrane was a permeable membrane
and allowed passing of drugs into the underside
membrane. Therefore, we inoculated the drug
on the inner shell membrane. This method of
treatment has beenused in various studies (15,
16). Ten eggs were assigned in each treatment.
The eggs were re-treated at 24 hr after the first
one (96 and 120 hr, days 4 and 5, of incubation
period).
The treated dosage of the methenamine was
selected following a preliminary study. In that study,
we used various dosages of methenamine for
treatment. The minimum gross abnormality and
relatively higher survival rate were observed at the
dose of 150 mg; hence the optimum treatment
dosage of methenamine was selected as 150 mg
for further experiments.
After injection, the orifice was closured by
warmed paraffin (Merck, Darmstadt, Germany). This
procedure has beenpreviously invented (17). On
day 6 of incubation period, 4 ml of albumin
was extracted from the pointed end of the eggs,
using 5ml syringe with a 21-gauge needle, to
allow the embryo to take some distance from the
eggshell. The eggshell was cut somehow to create
a window with a dimension of 2.5 cm to imagine
the surface of EEM using stereomicroscope (Luxeo
4D Stereozoom Microscope, Labomed, CA, USA)
attached to Canon SX200 camera supported by
Luxeo software. High resolution images (4000 ×
3000 pixels) were prepared with these equipment
and saved as *.tif files using a 14.5-inch PC (Intel
Core i3-390M, 2.66 GHz).
2.1.3. Vascular branching pattern analysis
Software including Digimizer® 4.3.0 (MedCalc
Software, Mariakerke, Belgium), ImageJ® 1.48
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(National Institutes of Health, Bethesda, Maryland,
USA) and MATLAB® (MathworksMatlab R2015a)
were used to analyze the captured images from
surface of EEM. For this computerized evaluation, a
certain part of themicroscopic imagewas selected.
The selected part included an area with the size
of 315 mm2 and 2987 × 2987pixels located
at the right-lateralaspect ofvitelline vascular
plexus. To detect the schematic template of the
vascular network, images were converted to
8-bit format and then analyzed. Ultimately, the
color scale of images was decreased to black
and white format and changed into skeletonized
picture. In skeletonized image, structural figure
of object was seen. Indices including vessels
area, total vessels length, and fractal dimension
(Df) value werethe representative of vascular
branching pattern (18) and were estimated by
analysis of processed images. The Df was
estimated with a box counting method on the
processed images as previously described (Figure
1) (15).
2.1.4. Morphometric analysis of capillary
density
Briefly, the contrast raised in the defined
part, inside the right-lateral vitelline plexus that
was previously selected. The effort was made
to choose the steady parts in each case to
desist subjectivity in analysis. The format of
selected parts changed to black and white.
The analysis was done on the areas with no
vessels. The percentage of the areas comprising
black pixels was quantified in five areas per
case. These black pixels were the representatives
of red color, or blood, in the original images.
The mean of all areas calculated in each case
was declared as the mean capillary area (MCA)
(19).
2.2. Effect of methenamine on the
expression of VEGF-A
qPCR (quantitative real-time PCR) was used
to determine the relative expression degree of
VEGF-A gene in the chicken EEM. The extraction
of total RNA from the EEM samples was done
usingRNeasy® mini kit (Qiagen, Chatsworth, CA)
based on the manufacture instructions (four
samples per group). The concentration of RNA (ng)
and its purity (260 nm: 280 nm) were assessed
by spectrophotometric method via NanoDrop
ND-1000 (NanoDrop ND-1000, Thermo Scientific,
Wilmington, DE, USA). TaKaRa Prime ScriptTM RT
reagent kits (Takara Bio, Inc., Shiga, Japan) was
used forthe synthesis of cDNA and the procedure
was done at 37°C for 15 min on 500 ng of the
total RNA sample. Duplicate qPCR reaction was
accomplished for each sample in Rotorgene Cycler
system (Rotorgene 3000 cycler system, Corbett
Research, Sydney, Australia) using a SYBR Green
assay (SYBR Premix Ex TaqTM II, Takara Bio, Inc.,
Shiga, Japan) based on the recommendedmethod.
The specific sequences of reference gene and
primers are presented in Table I (15). 86 bp segment
of the VEGF-A mRNA genes were amplified by the
primers. For the qPCR reaction,the following steps
were followed: 1) holdingh treatment at 95°C for
1 min, 2) forty cycles included 10 sec at 95°C for
denaturation, 15 sec at 60°C for primer annealing,
and 20 sec at 72°C for extension. Expression levels
were estimated relative to the expression levels of
the chosen reference gene.
2.2.1. Molecular modeling
To evaluate the probable interactions between
the methenamine and VEGF, a bioinformatic
analysis was performed (20). The ligand structure
was acquired from the PubChem database
(PubChem CID: 4101) and was optimized by using
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Discovery Studio 2017 (DS 2017) software. The
sequence of VEGF-A (Gallus gallus, Gene ID:
395909) was downloaded from the NCBI server,
and conformational structure of human VEGF-A
receptor-binding site was downloded from the
RCSB server (PDB code: 4KZN). The structure
of VEGF-A (4KZN) consist of a ligands. Tree
dimensional structure of VEGF-A (Gallus gallus)
was designed by SWISS-MODEL server. Partial
charges and hydrogen were add to the protein and
ligandand docking study was done to evaluate
the binding affinity of methenamine to VEGF-A via
Auto DockVina. The lowest energy ctructure was
choosed for further analysis.
Table I. The specific primers and reference gene sequences for quantitative real-time RT-PCR
Gene (Gallus gallus) Sequence (5’-3’) Product size (bp)
VEGF-A
Forward CAATTGAGA CCC TGGTGG AC 86




Figure 1. Calculation method of the fractal dimension (Df) value from the captured images. The oval is located right before the
first main branch of the right lateral vitelline vein and has included a size of 177 mm2 (A). The extracted areas were converted
into 8-bit format and processed to increase edge detection (B). Contrast was reversed for better detection of vessels(C). The Df
is measured from the slope of the regression line using the box-counting method (D).
2.3. Ethical consideration
All investigations were conducted in accordance
with the Guiding Principles for the Care and Use of
Research Animals and were approved by the ethics
committee of the Shahid Bahonar University (code:
IR.UK.VETMED.REC.1398.004).
2.4. Statistical analysis
Statistical analysis was performed using the
SPSS version 20 (Statistical Package for the Social
Sciences, SPSS Inc., Chicago, IL, USA). One-way
analysis of variance followed by Tukey’s test was
appliedto assess the significance of differencesin
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the vascular parameters and gene expression.
A p-value of <0.05 was considered statistically
significant.
3. Results
On day 6 of incubation, when the egg shell
windowwas created for taking photos, Hamburger-
Hamilton developmental stages of embryos were
at 29. In the control group, a fine network of vitelline
vessels surrounded the embryo (Figure 2a). In
the methenamine group, an abnormal template
of EEM vascular network was seen in embryos.
Vascular disturbance was observed by a very
obvious decreased branching (Figure 2b). The
analysis of vascular branching pattern following
methenaminetreatment is presented in Table II.
Methenamine in dosage of 150 mg/kg alters
the vascular branching pattern. Methenamine
decreasedthe Df value of the vascular network
in comparison with the controls (control, 1.338 ±
0.012; and 150 mg/kg eggweight, 1.222 ± 0.020
(95% CI -0.165 to -0.066); p < 0.001).
Capillary density indicesaredemonstrated in
Figure 3. MCA decreasedsignificantly in the
vascular plexus of the treated embryos in group
that receive methenamine (control, 15.59 ± 1.66;
methenamine, 14.48 ± 1.01; p = 0.024.
3.1. Expression of VEGF-A
The relative expression of the VEGF-A gene
was assessed using qPCR on day 6 of the
incubation period. The relative mRNA expression
levels of VEGF-A reduced in the methenamine-
treated group compared to the control group
(Figure 4).
3.2. Methenamine bound to VEGF-A
by molecular docking
The conformational structure of VEGF-A (Gallus
gallus) was created by SWISS-MODEL server. The
generated structure was assessed by analyzing
PROCHECK srver and the Ramachandran plot is
showed in Figure 5. PROCHECK data for residues
in most favored regions was 90.4%, residues in
additional allowed regions was 8.2%, residues
in generously allowed regions was 1.4%, and
residues in disallowed regions was 0.0%. These
analysis showed that a good structures were
generated. The conformational analysis of VEGF-
A protein is as bellow: molecular weight: 9537.99,
the number of amino acids: 83; total number of
negatively charged residues (Asp + Glu): 12; total
number of positively charged residues (Arg + Lys):
7.
The docking technique was performed to
evaluate the binding affinity between protein and
ligand. The acquired data confirmed that the active
site of VEGF-A was docked with methenamine to
make nine conformation. As showed in the binding
structure (Figure 6), methenamine was bound to
the active site of VEGF-A by hydrophobic and
vandervase interaction with Ser72, Asn52, Tyr16,
Glu15, Phe73, and Leu74.
Table II. Vascular branching pattern analysis following methenaminetreatment
Parameters Group
Control Methenamine (150 mg/kg)
Vessels area (%) 30.22 ± 1.82𝑎 24.73 ± 2.75𝑏
Total vessels length (Pixel) 40.51𝑎 28.91𝑏
∗Values are Mean ± standard error of mean;Values in a row followed by different superscripts differ significantly (p < 0.05)
Page 584 https://doi.org/10.18502/ijrm.v13i8.7497
International Journal of Reproductive BioMedicine Angiogenesis and VEGF-Aexpression after methenamine treatment in CAM
Figure 2. Embryonated eggs were administered at 96 and120 hrafterthe incubation. (A) Control embryo with normal extra-
embryonic membrane vasculature is seen. (B) Embryonated egg received methenamineat the dosage of 150 mg/kg eggweight.
Vascular disruption is demonstrated by decreased branching.
Figure 3. Calculation of mean capillary area (MCA) for the demonstration of the effect of methenamine on angiogenesis in CAM.
Comparison was done between control (n = 10) and methenamine (n = 10)-treated group (error bars show standard error of mean;
p < 0.05, One-way ANOVA).
Figure 4. Relative expression of mRNA levels of VEGF-A gene in methenamine-treated group in comparison with control (error
bars show standard error of mean; *p < 0.05, One-way ANOVA).
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Figure 5. Ramachandran plot for protein model of VEGF-A (Gallus gallus). PROCHECK source information for residues in most
favored regions is 90.4% and confirms that a good-quality model would be expected.
Figure 6. Binding mode of methenamine with VEGF-A (Gallus gallus). (A) 3D structure of original ligand. (B) Platform of
methenamine inserted in the VEGF-Abinding site. (C and D) Hydrophobic and vandervase interaction between methenamine
and amino acid residues of the nearby binding site.
4. Discussion
Methenamine is a commonly used medicine
for the treatment of urinary system infections.
The most important concern about taking
any medication is the side effects of drugs.
Additionally, toxicity characteristic of drug during
gestation is of great concern. Inthe present
study, we studied the effect of methenamine
administration on the early chicken embryo’s
angiogenesis as a model for drug consumption
in early pregnancy. Methenamine at the
dose of 150 mg/kg significantly reduced
angiogenesis in extraembryonic chorioallantoic
membrane.Andelman observed that the
treatment of 531 women during pregnancy
with methenaminehippurate had no signs of
fetal injury (1). Undocumented surveillance study
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between 1985 and 1992 on the newbornsexposed
to methenamine showed 3.8% malformation
(21). Generally, the book of “drugs in pregnancy
and lactation” emphasizes on the safety of
methenamine in pregnant women. On the other
hand, in this book, a collaborative perinatal
projectisavailable that found an association
between the consumption of drugs in pregnancy
and fetal malformations (21).
In the present study, we found that methenamine
reduced angiogenesis. To the best of our
knowledge, there is no study in the literature
about the antiangiogenic or angiogenic property
of methenamine. On the other hand, angiogenesis
disturbance during pregnancy could lead to
embryonic or fetal growth abnormalities (10). After
fertilization and entrance of fertilized ova into
the uterus, there arethree important parts for
the normal growth of embryo and maintenance
of normal pregnancy in whichangiogenesis
has a critical role to play: (1) uterus, (2) embryo
or fetus, and (3) placenta. The endometrium,
placenta, and decidua are rich sources of
angiogenic growth factors and since the uterus
and its enclosures require increased supply
of blood during gestation, the production and
development of new vessels occur (22, 23).
Angiogenesis in embryo is indispensable for the
formation of organs and their final evolution.
Angiogenesis in placental tissue begins as
early as three weeks post conception and
continues throughout pregnancy (24). Meegdes
and colleagues found that chorionic villous
vascularization in patient with fetal death was
significantly lower than in women undergoing
legal abortion (10). There is also evidence that
pre-eclampsia was caused by disturbances in
vascular growth in the fetomaternal unit (25).
Intrauterine growth restriction , another reason
for perinatal morbidity and mortality induced the
developmental disorder of the villous branches
and pathological changes in the vasculature
of villous in placenta (26). All of this evidence
suggest that any disruption in the angiogenesis
process in embryo-related structures can lead
to insufficiency in the normal development of
the embryo/fetus.However, this may not be the
only way to disturb the pregnancy process by
methenamine and other probable side effects
of the drug during pregnancy should befurther
investigated.
Methenamine belongs to a class of organic
compounds named 1, 3, 5-Triazine. 1, 3, 5-
Triazine is a scaffold that has many derivatives.
These compounds were extensively studied
because of theirdifferent biological effects such
as antimicrobial, antiviral, and anti-inflammatory
(27-29). Additionally, great attention has been paid
to antitumor activity of 1, 3, 5-triazine derivatives
(30). It is shown that 2-hydroxy-4, 6-diamino-[1,
3, 5] triazines (a 1,3,5-Triazine derivative) have
antiangiogenic property via potent inhibitory
effect on VEGF-R2 tyrosine kinase (flk-1/KDR)
that functions as the main mediator of VEGF-
induced endothelial proliferation, survival, and
migration (31). There areother studies in the
literature about antiangiogenic effect of 1,3,5-
Trazine different derivatives (32, 33). Unlike the
other members of 1,3,5-Triazinecompounds,there
are no studies that provide evidence on the
anticancer properties of methenamine salts, but
formaldehyde released from methenamine in
acidic PH can inhibit the proliferation and induce
apoptosis of cancer cells (34). Antiangiogenic
properties of methenamine that revealed inthis
study could makethe role of methenamine in
treating cancers more prominent.
In the present study, we demonstrated
that methenamine at the dose of 150 mg/kg
reduced VEGF-A related mRNA. This finding
confirmed the fact that methenamine certainly
caused an angiogenic disorder. VEGF-A is best
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known as a key regulator of the angiogenesis
process. It is demonstrated that transgenic
mice forsingle VEGF-A allele had abnormal
disturbed angiogenesis and subsequent
embryonic death (35). So, keeping tight control
of VEGF-A expression is the important part
of normal developmental angiogenesis. The
mechanism by which methenamine reduced
angiogenesis in thepresent study is unknown,
but the amount of VEGF-A was definitely
decreasedand could be one of the main reasons
for this incident.
In the current study, in silico molecular-
modeling assay, using a Gallus gallus model
of VEGF-A protein, were conducted toprecisely
search for the target of methenamine as
an antiangiogenic agent. We found a good
binding relationship between methenamine
and VEGF-A protein through molecular
docking. This may provide a link between
methenamine exposure and vascular
defects.
5. Conclusion
In conclusion, chick embryo may be a good
preclinical model to assess the adverse effects
of drugs during early stages of embryogenesis,
in which the evaluation cannot be made in
human or other animal trials due to the ethical
reasons, and will provide data about probable
consequence of drug consumption during
gestation to clinicians for recommendation of drug
to pregnant women. In this study, we reported
the anti-angiogenicproperty of methenamine for
the first time in the literature. Additionally, the
results reported in this studyallow us to suggest
that the use of the methenamine during pregnancy
should be considered potentially as vasculo-
toxic and because undisturbed angiogenesis
is essential for normal fetal growth, caution
should be exercised when prescribing itduring
pregnancy.
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